4D Molecular Therapeutics Ownership | Who Owns 4D Molecular Therapeutics?


OverviewForecastRevenueFinancialsChart

4D Molecular Therapeutics Ownership Summary


4D Molecular Therapeutics is owned by 77.30% institutional investors, 3.88% insiders, and 18.82% retail investors. Blackrock is the largest institutional shareholder, holding 9.94% of FDMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.32% of its assets in 4D Molecular Therapeutics shares.

FDMT Ownership Benchmark


TypeName% Inst% Insiders% Retail
Stock4D Molecular Therapeutics77.30%3.88%18.82%
SectorHealthcare Stocks 279.19%10.62%-189.81%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock4.90M9.94%$102.79M
Blackrock funding, inc. /de4.92M8.86%$27.41M
Ra capital management4.56M8.21%$25.42M
Goldman sachs group4.27M7.70%$23.81M
Vr adviser2.95M5.31%$16.44M
Vanguard group2.86M5.15%$15.93M
Bvf inc/il2.67M4.81%$14.88M
Janus henderson group2.25M4.05%$12.54M
Morgan stanley1.46M2.96%$30.65M
Novo1.50M2.70%$8.36M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Vr adviser2.95M1.13%$16.44M
Novo1.50M0.51%$8.36M
Bvf inc/il2.67M0.50%$14.88M
Decheng capital400.00K0.48%$2.23M
Redmile group1.20M0.46%$6.67M
Ra capital management4.56M0.34%$25.42M
Privium fund management b.v.121.00K0.15%$673.97K
Arrowmark colorado794.60K0.06%$4.43M
Peloton wealth strategists25.00K0.06%$139.00K
Velan capital investment management lp10.00K0.05%$55.70K

Top Buyers

HolderShares% AssetsChange
Millennium management1.42M0.00%1.34M
Goldman sachs group4.27M0.00%683.94K
Blackrock4.90M0.00%612.35K
Jpmorgan chase820.07K0.00%504.09K
Norges bank500.82K0.00%500.82K

Top Sellers

HolderShares% AssetsChange
Bvf inc/il2.67M0.50%-4.71M
Viking global investors lp---2.93M
Vr adviser2.95M1.13%-1.45M
Braidwell lp---1.23M
Casdin capital---1.15M

New Positions

HolderShares% AssetsChangeValue
Norges bank500.82K0.00%500.82K$2.79M
Hudson bay capital management lp113.30K0.01%113.30K$2.38M
Raymond james financial112.90K0.00%112.90K$628.88K
Bnp paribas arbitrage, snc95.42K0.00%95.42K$531.51K
Hrt financial lp83.42K0.00%83.42K$464.00K

Sold Out

HolderChange
Innealta capital-4.00
Nelson, van denburg & campbell wealth management group-8.00
Farther finance advisors-14.00
Allspring global investments-27.00
Allworth financial lp-28.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025125-14.38%43,088,441-8.05%771.09%47-43.37%6036.36%
Dec 31, 20241442.86%46,861,479-18.79%840.78%829.33%442.33%
Sep 30, 2024140-4.11%57,700,8380.63%1030.77%76-7.32%4210.53%
Jun 30, 2024146-6.41%57,338,9551.87%1160.89%82-21.15%382.70%
Mar 31, 202415633.33%56,284,67532.64%1140.97%10462.50%3732.14%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.54M3.32%-
Vanguard Total Stock Mkt Idx Inv1.54M3.32%-
iShares Russell 2000 ETF1.18M2.55%579.00
SPDR® S&P Biotech ETF986.40K2.13%14.03K
Janus Henderson Global Life Sciences D952.09K2.06%66.22K
Janus Henderson Global Life Sciences952.09K2.06%49.13K
Federated Hermes MDT Small Cap Core IS866.66K1.87%866.66K
Federated Hermes MDT SCC Institutional866.66K1.87%866.66K
Janus Global Life Science AUSD738.42K1.59%-6.66K
Janus Henderson Glb Life Scn I2 USD723.89K1.56%-14.53K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 16, 2024Bizily Scott Chief Legal OfficerSell$8.16K
Aug 19, 2024Bizily Scott Chief Legal OfficerSell$7.50K
Jul 16, 2024Bizily Scott Chief Legal OfficerSell$47.44K
Jul 11, 2024Bizily Scott Chief Legal OfficerSell$49.90K
Jul 10, 2024Kirn David Chief Executive OfficerSell$290.60K

Insider Transactions Trends


DateBuySell
2024 Q4--
2024 Q3-6
2024 Q2-6
2024 Q1-13
2023 Q4-2

FDMT Ownership FAQ


Who Owns 4D Molecular Therapeutics?

4D Molecular Therapeutics shareholders are primarily institutional investors at 77.30%, followed by 3.88% insiders and 18.82% retail investors. The average institutional ownership in 4D Molecular Therapeutics's industry, Biotech Stocks , is 63.96%, which 4D Molecular Therapeutics exceeds.

Who owns the most shares of 4D Molecular Therapeutics?

4D Molecular Therapeutics’s largest shareholders are Blackrock (4.9M shares, 9.94%), Blackrock funding, inc. /de (4.92M shares, 8.86%), and Ra capital management (4.56M shares, 8.21%). Together, they hold 27.01% of 4D Molecular Therapeutics’s total shares outstanding.

Does Blackrock own 4D Molecular Therapeutics?

Yes, BlackRock owns 9.94% of 4D Molecular Therapeutics, totaling 4.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 102.79M$. In the last quarter, BlackRock increased its holdings by 612.35K shares, a 14.29% change.

Who is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested?

Vr adviser is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.13% of its assets in 2.95M 4D Molecular Therapeutics shares, valued at 16.44M$.

Who is the top mutual fund holder of 4D Molecular Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of 4D Molecular Therapeutics shares, with 3.32% of its total shares outstanding invested in 1.54M 4D Molecular Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools